Low-molecular-weight heparin for routine hemodialysis

Hemodialysis International

Volumn 12, Issue SUPPL. 2, 2008, Pages

  Davenport, Andrew ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Enoxaparin; LMWH; Tinzaparin

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING DISORDER; CONFERENCE PAPER; COST CONTROL; DRUG CHOICE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUROPE; EXTRACORPOREAL CIRCULATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY FAILURE; SINGLE DRUG DOSE;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; THROMBOSIS;

EID: 53349173408     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00322.x     Document Type: Conference Paper

References (12)

1. Davenport A. Anticoagulation options for intermittent haemodialysis (review). Minerva Urol Nefrol. 2006; 58:171-180.
2. Davenport A. Anticoagulation in patients with acute renal failure treated with continuous renal replacement therapies. Hemodial Int. 1998; 2:41-59.
3. Stöbe J, Siegemund A, Achenbach H, Preiss C, Preiss R. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. Int J Clin Pharmacol Ther. 2006; 44:455-465.
4. Guillet B, Simon N, Sampol JJ, et al. Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant. 2003; 18:2348-2353.
5. Davenport A, Lai KN, Hertel J, Caruana RJ. Anticoagulation. In: Daugirdas JT, Blake PG, Ing TS eds. Handbook of Dialysis. 4th ed. Philadelphia, USA: Wolters Kluwer Health. 2007; 204-218.
6. Isla A, Gascón AR, Maynar J, et al. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. Clin Ther. 2005; 27:1444-1451.
7. Brophy DF, Carr ME Jr, Martin EJ, Venitz J, Gehr TW. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies. J Clin Pharmacol. 2006; 46:887-894.
8. Davenport A. Heparin-induced thrombocytopenia during renal replacement therapy. Hemodial Int. 2004; 8:295-303.
9. Lord H, Jean N, Dumont M, Kassis J, Leblanc M. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol. 2002; 22:58-66.
10. Hofbauer R, Moser D, Frass M, et al. Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int. 1999; 56:1578-1583.
11. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: A meta-analysis of randomized trials. J Am Soc Nephrol. 2004; 15:3192-3206.
12. European Best Practice Guidelines Expert Group on Hemodialysis European Renal Association. Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant. 2002; 17(Suppl 7):63-71.